Nuvation Bio Inc. Increase (Decrease) in Accounts Payable
Nuvation Bio Inc. (NUVB) reported Increase (Decrease) in Accounts Payable of $3.11 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- Nuvation Bio Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$9.85M, a 182.86% decline year-over-year.
- Nuvation Bio Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $12.96M, a 209.29% increase year-over-year.
- Nuvation Bio Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$5.88M.
- Nuvation Bio Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$7.06M, a 198.47% decline year-over-year.
- Nuvation Bio Inc. increase (decrease) in accounts payable for fiscal 2025 was $3.13M.
- Nuvation Bio Inc. increase (decrease) in accounts payable for fiscal 2024 was -$1.65M, a 2462.86% decline from fiscal 2023.
- Nuvation Bio Inc. increase (decrease) in accounts payable for fiscal 2023 was $70.00K.
- Nuvation Bio Inc. increase (decrease) in accounts payable for fiscal 2022 was -$1.79M, a 195.97% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$9.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.11M 10-Q · filed 2026-08-06 | -$2.77M derived: sum of 3 quarters · filed 2026-08-06 | -$9.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $12.96M 10-Q · filed 2026-05-04 | $7.08M derived: sum of 2 quarters · filed 2026-05-04 | $16.00K derived: sum of 3 quarters · filed 2026-05-04 | $11.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$5.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$12.94M derived: sum of 2 quarters · filed 2026-03-02 | -$1.06M derived: sum of 3 quarters · filed 2026-08-06 | $3.13M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$7.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $4.82M derived: sum of 2 quarters · filed 2026-08-06 | $9.01M 10-Q · filed 2025-11-03 | $2.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $11.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $16.07M 10-Q · filed 2026-08-06 | $10.04M derived: sum of 3 quarters · filed 2026-08-06 | $17.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $4.19M 10-Q · filed 2026-05-04 | -$1.84M derived: sum of 2 quarters · filed 2026-05-04 | $5.33M derived: sum of 3 quarters · filed 2026-05-04 | $2.31M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$6.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.14M derived: sum of 2 quarters · filed 2026-03-02 | -$1.88M derived: sum of 3 quarters · filed 2026-03-02 | -$1.65M 10-K · filed 2026-03-02 |
| 2024-09-30 | $7.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $4.15M derived: sum of 2 quarters · filed 2025-11-03 | $4.38M 10-Q · filed 2025-11-03 | $4.21M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | -$3.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$2.79M 10-Q · filed 2025-08-07 | -$2.96M derived: sum of 3 quarters · filed 2025-08-07 | -$3.16M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $227.00K 10-Q · filed 2025-05-07 | $63.00K derived: sum of 2 quarters · filed 2025-05-07 | -$141.00K derived: sum of 3 quarters · filed 2025-05-07 | -$509.00K derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$164.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$368.00K derived: sum of 2 quarters · filed 2025-03-06 | -$736.00K derived: sum of 3 quarters · filed 2025-03-06 | $70.00K 10-K · filed 2025-03-06 |
| 2023-09-30 | -$204.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$572.00K derived: sum of 2 quarters · filed 2024-11-06 | $234.00K 10-Q · filed 2024-11-06 | -$622.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$368.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $438.00K 10-Q · filed 2024-08-05 | -$418.00K derived: sum of 3 quarters · filed 2024-08-05 | -$10.15M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $806.00K 10-Q · filed 2024-05-14 | -$50.00K derived: sum of 2 quarters · filed 2024-05-14 | -$9.78M derived: sum of 3 quarters · filed 2024-05-14 | -$6.73M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$856.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$10.59M derived: sum of 2 quarters · filed 2024-02-29 | -$7.53M derived: sum of 3 quarters · filed 2024-02-29 | -$1.79M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$9.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$6.68M derived: sum of 2 quarters · filed 2023-11-02 | -$930.00K 10-Q · filed 2023-11-02 | -$2.10M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $3.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $8.80M 10-Q · filed 2023-08-03 | $7.63M derived: sum of 3 quarters · filed 2023-08-03 | $8.27M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $5.75M 10-Q · filed 2023-05-04 | $4.58M derived: sum of 2 quarters · filed 2023-05-04 | $5.21M derived: sum of 3 quarters · filed 2023-05-04 | $3.67M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$537.00K derived: sum of 2 quarters · filed 2023-03-15 | -$2.08M derived: sum of 3 quarters · filed 2023-03-15 | $1.86M 10-K · filed 2023-03-15 |
| 2021-09-30 | $636.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$906.00K derived: sum of 2 quarters · filed 2022-11-03 | $3.03M 10-Q · filed 2022-11-03 | $1.37M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $2.40M 10-Q · filed 2022-08-04 | $732.00K derived: sum of 3 quarters · filed 2022-08-04 | $2.96M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $3.94M 10-Q · filed 2022-05-09 | $2.27M derived: sum of 2 quarters · filed 2022-05-09 | $4.51M derived: sum of 3 quarters · filed 2022-05-09 | $3.73M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $567.00K derived: sum of 2 quarters · filed 2022-02-28 | -$206.00K derived: sum of 3 quarters · filed 2022-02-28 | $34.00K 10-K · filed 2022-02-28 |
| 2020-09-30 | $2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.46M derived: sum of 2 quarters · filed 2021-11-10 | $1.70M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$773.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$533.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $240.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |